Clinical trials: gemcitabine hydrochloride
Lung Cancer
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer.
- Trial name
- NCT01443078
- Testing
- pemetrexed, cisplatin, Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Pancreatic Cancer
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
This is an open-label, single arm, multi-center, Phase II trial to evaluate the progression free survival in patients with metastatic adenocarcinoma of the pancreas treated with a hedgehog inhibitor (GDC-0449) in combination with…
- Trial name
- NCT01088815
- Testing
- Gemcitabine, nab-Paclitaxel, GDC-0449
- Where
- 3 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer, Stage IV Pancreatic Cancer
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with nab-paclitaxel and gemcitabine.
- Trial name
- NCT02005315
- Testing
- Vantictumab, Nab-Paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
B-cell Lymphoma
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
This study is designed to evaluate the safety and efficacy of glofitamab or mosunetuzumab in combination with gemcitabine and oxaliplatin (Glofit-GemOx or Mosun-GemOx) in participants with relapsed or refractory (R/R) diffuse…
- Trial name
- NCT04313608
- Testing
- Glofitamab, Gemcitabine, Oxaliplatin
- Where
- 3 sites in Australia
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Unresectable Pancreatic Cancer
Regional Versus Systemic Chemotherapy in the Treatment of Unresectable Pancreatic Cancer
Systemic chemotherapy with cytotoxic drug is of limited effectiveness in advanced pancreatic cancer patients. Gemcitabine has been used as the first-line drug for advance pancreatic cancer for over two decades and combinations of…
- Trial name
- NCT01665625
- Testing
- regional interventional chemotherapy group
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Air Force Military Medical University, China
Healthy
A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers
The purpose of Part 1 of this First-in-Human trial is to evaluate the safety and tolerability after single ascending oral doses of IOA-289 given to healthy male subjects, compared to placebo.
- Trial name
- NCT05027568
- Testing
- IOA-289, Nab paclitaxel / gemcitabine
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- iOnctura
Pancreas Cancer
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
The primary objective of this study is to assess the impact of bethanechol therapy on R0 resection rates. The safety objective will be assessment of the safety and tolerability of bethanechol in combination with gemcitabine and…
- Trial name
- NCT05241249
- Testing
- Bethanechol, Gemcitabine, nab-paclitaxel
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Susan E. Bates
Ovarian Cancer, Fallopian Tube Cancer
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III
- Trial name
- NCT04701645
- Testing
- Microdevice
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Non-Small Cell Lung Cancer (NSCLC)
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
This is a randomized, open-label, multicenter, Phase 3 study, comparing efficacy and safety of eribulin with TPC in subjects with advanced and disease progression following at least two prior regimens for advanced disease, which…
- Trial name
- NCT01454934
- Testing
- Eribulin, TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
- Where
- 83 sites in United States, Australia and 12 more
- Volunteers
- 540 people
- Sponsor
- Eisai Inc.
Advanced Pancreatic Carcinoma
A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer
A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy
- Trial name
- NCT05257122
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Solid Tumor, Breast Cancer
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02784795
- Testing
- LY3039478, Taladegib, Abemaciclib
- Where
- 11 sites in United States, Denmark and 2 more
- Volunteers
- 94 people
- Sponsor
- Eli Lilly and Company
Biliary Tract Cancer, Gallbladder Cancer
Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
The purpose of this study is to determine whether fit patients (with ECOG performance score of 0-1) with advanced biliary tract cancer (ABC) benefit from chemotherapy in the second-line setting (after prior therapy with cisplatin…
- Conditions
- Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma, Ampullary Cancer
- Trial name
- ABC06 (NCT01926236)
- Testing
- Active Symptom Control, L-folinic acid, 5 FU
- Where
- 17 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- The Christie NHS Foundation Trust
Metastatic NSCLC - Non-Small Cell Lung Cancer
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Metastatic non-small cell lung cancer is often treated with a combination of chemotherapy and immunotherapy. In patients over the age of 70, some are already in poor health and frail, requiring assistance with daily activities…
- Trial name
- NCT07020065
- Testing
- Cemiplimab, Carboplatin, Pemetrexed & Gemcitabine
- Where
- 18 sites in Switzerland
- Volunteers
- 156 people
- Sponsor
- Swiss Cancer Institute
Locally Advanced Perihilar Cholangiocarcinoma
A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)
This study is a prospective, single-arm, phase II clinical trial designed to evaluate the safety and efficacy of PD-L1 monoclonal antibody combined with chemoradiotherapy as a bridge to liver transplantation in patients with…
- Trial name
- ACHIEVE-LT (NCT07471165)
- Testing
- PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.
- Conditions
- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
- Trial name
- NCT03684811
- Testing
- FT-2102, Azacitidine, Nivolumab
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 93 people
- Sponsor
- Forma Therapeutics, Inc.
Pancreatic Cancer
Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer
This is a phase Ⅱ Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Gemcitabine in Patients With Resected Pancreatic Cancer.
- Trial name
- NCT01396681
- Testing
- gemcitabine and cisplatin
- Where
- 2 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Seoul National University Hospital
Transitional Cell Carcinoma
Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer
The purpose of this study is to test the effectiveness, safety and side effects of two chemotherapy drugs (gemcitabine and cisplatin) when combined with surgery after chemotherapy for patients with upper urinary tract cancer.
- Trial name
- NCT00696007
- Testing
- Gemcitabine and cisplatin, Retrospective comparison
- Where
- United States
- Sponsor
- Lahey Clinic
Neoplasms, Neoplasm Metastasis
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Phase 1b: To determine the safe and tolerable dose of galunisertib in combination with gemcitabine in patients with solid malignancy Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable…
- Conditions
- Neoplasms, Neoplasm Metastasis, Pancreatic Cancer
- Trial name
- NCT01373164
- Testing
- Galunisertib, Gemcitabine
- Where
- 24 sites in United States, Belgium and 4 more
- Volunteers
- 170 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
LBH589 and Gemcitabine in the Treatment of Solid Tumors
This will be a single center phase I dose escalation trial. LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
- Trial name
- NCT00550199
- Testing
- LBH589, Gemcitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- SCRI Development Innovations, LLC
Nasopharyngeal Carcinoma
Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
This is a Phase III randomized controlled multi-center trial comparing anlotinib plus Gemcitabine/Cisplatin with placebo plus Gemcitabine/Cisplatin in previous untreated patients with recurrent/metastatic Nasopharyngeal…
- Trial name
- NCT03601975
- Testing
- Gemcitabine/Cisplatin
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.